How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?

20260 citationsJournal Articlediamond Open Access

Authors

Frigg Å. Sommervoll · University of Bergen

Henrik Horndalsveen · Oslo University Hospital

Dag Einar Sommervoll

Jussi Koivonen · Oulu University Hospital

Tarje Onsøien Halvorsen · Norwegian University of Science and Technology

Bjørn Henning Grønberg · Norwegian University of Science and Technology

Marianne Aanerud · Haukeland University Hospital

Abstract

The HRQoL remained stable during chemoradiotherapy and durvalumab treatment in stage III NSCLC patients. Impaired lung function was associated with modestly lower HRQoL, though larger studies are needed to confirm subgroup effects.

Topics & Keywords

Lung Cancer Diagnosis and Treatment Chronic Obstructive Pulmonary Disease (COPD) Research Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Publication Details

Published in: Acta Oncologica

Volume 65, pp. 232-240

DOI: 10.2340/1651-226x.2026.45040

Field-Weighted Citation Impact: 0.00

Command Palette

How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?

Authors

Abstract

Topics & Keywords

Publication Details